2-(2-isopropoxy-phenoxy)-ethylamine | 273722-74-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(2-isopropoxy-phenoxy)-ethylamine
• 英文别名: 2-(2-Isopropoxyphenoxy)ethylamine；2-(2-propan-2-yloxyphenoxy)ethanamine
• CAS: 273722-74-0
• 化学式: C₁₁H₁₇NO₂
• 分子量: 195.261
• InChiKey: HSAPQQCIVXSCQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-isopropoxy-phenoxy)-ethylamine 在 钾硼氢 作用下， 以 甲醇 为溶剂， 反应 19.0h， 生成 2-(2-propan-2-yloxyphenoxy)-N-[(3-thiophen-3-ylphenyl)methyl]ethanamine
  参考文献：
  名称：

  迈向结合D2和5-HT1A受体活性的新一代潜在抗精神病药。

  摘要：

  我们报告发现和合成的新型，潜在的抗精神病药化合物在同一分子中结合有效的多巴胺D2受体拮抗剂和5-羟色胺5-HT1A受体激动剂的性质。我们描述了导致我们有希望的衍生物的结构-活性关系：N-[（2,2-二甲基-2,3-二氢-苯并呋喃-7-酰氧基）乙基] -3-（环戊-1-烯基）-苯甲酰胺16。后者对D2和5-HT1A受体具有高亲和力，而对5-HT2A位点仅具有较弱的亲和力。在信号转导的细胞模型中，16充当rD2受体的沉默拮抗剂，同时激活h5-HT1A受体，其功效至少相当于典型的5-HT1A激动剂（+/-）-8-OH-DPAT。这些双重作用赋予产品独特的药理作用。在可预测阳性症状的行为模型中，16的活性与典型的抗精神病药氟哌啶醇相当，而没有致晕作用。尽管它会在大鼠中产生5-HT1A受体激活的行为特征，但它们的剂量比（+/-）-8-OH-DPAT的剂量高100倍。我们认为16种D2和5-HT1A作

  DOI：

  10.1021/jm061180b
• 作为产物：
  描述：

  2-异丙氧基苯酚 在 盐酸 、 偶氮二甲酸二叔丁酯 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 2-(2-isopropoxy-phenoxy)-ethylamine
  参考文献：
  名称：

  Inhibitors of the glycine transporter type-2 (GlyT-2): synthesis and biological activity of benzoylpiperidine derivatives

  摘要：

  A series of benzoylpiperidine analogs related to 4a was prepared, and their ability to inhibit the uptake of [C-14]-glycine in COS7 cells transfected with human glycine transporter type-2 (GlyT-2) was evaluated. Small structural changes to the benzoylpiperidine region of the molecule led to a significant decrease in GlyT-2 inhibitory activity. In contrast, the distal aryl ring was more tolerant to functional group modifications and could accommodate a variety of substitutes at the C-2 or C-3 positions. Comparable activities to 4a were obtained by replacing the anilino nitrogen with an ether linkage 27 or by exchanging the isopropoxy ether moiety with an isopropyl amino group 15. A distinct preference for a 2-carbon tether (n = 1) was observed relative to the corresponding 3-carbon homolog (n = 2). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.044

文献信息

• Aryl piperidine amides
  申请人：Huang Q. Charles

  公开号：US20050049239A1

  公开（公告）日：2005-03-03

  The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.

  该发明提供了新颖的GlyT2抑制化合物，可用于调节、治疗或预防：焦虑症；需要治疗受伤哺乳动物神经组织的状况；适合通过神经营养因子管理治疗的状况；神经系统紊乱；或肥胖症；与肥胖相关的疾病。
• 3-alkoxybenzylamine derivatives and their use as medicines for treating schizophrenia
  申请人：Pierre Fabre Medicament

  公开号：US06350913B1

  公开（公告）日：2002-02-26

  The present invention relates to novel 3-alkoxybenzylamine derivatives of general formula (1): which are useful as medicinal products and in particular as antipsychotic agents.

  本发明涉及一种新型3-烷氧基苯基胺衍生物，其一般式为(1)，可用作药物，特别是作为抗精神病药物。
• Aryl Piperidine Amides
  申请人：Huang Q. Charles

  公开号：US20080009521A1

  公开（公告）日：2008-01-10

  The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.

  本发明提供了新型GlyT2抑制化合物，可用于调节、治疗或预防：抗焦虑障碍；需要治疗受损哺乳动物神经组织的状况；可通过给予神经营养因子进行治疗的状况；神经系统疾病；或肥胖症；肥胖相关疾病。
• Discovery of a new series of 5-HT1A receptor agonists
  作者：Silvia Franchini、Adolfo Prandi、Claudia Sorbi、Annalisa Tait、Annamaria Baraldi、Piero Angeli、Michela Buccioni、Antonio Cilia、Elena Poggesi、Paola Fossa、Livio Brasili

  DOI：10.1016/j.bmcl.2010.01.030

  日期：2010.3

  Starting from compounds previously identified as alpha(1)-adrenoceptor antagonists that were also found to bind to the 5-HT1A receptor, in an attempt to separate the two activities, a new series of 5-HT1A receptor agonists was identified and shown to have high potency and/or high selectivity. Of these, compound 13, which combines high selectivity (5-HT1A/alpha(1) = 151) and good agonist potency (pD(2) = 7.82; E-max = 76), was found to be the most interesting. (C) 2010 Elsevier Ltd. All rights reserved.
• NOUVEAUX DERIVES DE 3-ALKOXYBENZYLAMINES ET LEUR UTILISATION A TITRE DE MEDICAMENTS POUR LE TRAITEMENT DE LA SCHIZOPHRENIE
  申请人：PIERRE FABRE MEDICAMENT

  公开号：EP1135360A1

  公开（公告）日：2001-09-26